Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trials of 9-amino-20(S)-camptothecin in Boston.
Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Eder JP, et al. Among authors: kinchla n. Ann N Y Acad Sci. 1996 Dec 13;803:247-55. doi: 10.1111/j.1749-6632.1996.tb26394.x. Ann N Y Acad Sci. 1996. PMID: 8993518 Clinical Trial.
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Eder JP Jr, et al. Among authors: kinchla n. J Clin Oncol. 2002 Sep 15;20(18):3772-84. doi: 10.1200/JCO.2002.02.082. J Clin Oncol. 2002. PMID: 12228197 Clinical Trial.
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Hamilton AL, et al. Among authors: kinchla n. J Clin Oncol. 2005 Sep 1;23(25):6107-16. doi: 10.1200/JCO.2005.01.136. J Clin Oncol. 2005. PMID: 16135477 Clinical Trial.
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Richardson PG, et al. Among authors: kinchla nm. Blood. 1998 Aug 1;92(3):737-44. Blood. 1998. PMID: 9680339 Free article. Review.
Decrease in operative risk of reoperative valve surgery.
Cohn LH, Aranki SF, Rizzo RJ, Adams DH, Cogswell KA, Kinchla NM, Couper GS, Collins JJ Jr. Cohn LH, et al. Among authors: kinchla nm. Ann Thorac Surg. 1993 Jul;56(1):15-20; discussion 20-1. doi: 10.1016/0003-4975(93)90397-z. Ann Thorac Surg. 1993. PMID: 8328847
13 results